Clofazimine for treatment of multidrug-resistant non-tuberculous mycobacteria
- 1 October 2021
- journal article
- research article
- Published by Elsevier in Pulmonary Pharmacology & Therapeutics
- Vol. 70, 102058
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosisThorax, 2015
- Mycobacterium abscessusComplex Infections in HumansEmerging Infectious Diseases, 2015
- Epidemiology of Human Pulmonary Infection with Nontuberculous MycobacteriaClinics in Chest Medicine, 2015
- Treatment outcomes of refractory MAC pulmonary disease treated with drugs with unclear efficacyJournal of Infection and Chemotherapy, 2014
- Safety and availability of clofazimine in the treatment of multidrug and extensively drug-resistant tuberculosis: analysis of published guidance and meta-analysis of cohort studiesBMJ Open, 2014
- Whole-genome sequencing to identify transmission of Mycobacterium abscessus between patients with cystic fibrosis: a retrospective cohort studyThe Lancet, 2013
- High efficacy of clofazimine and its synergistic effect with amikacin against rapidly growing mycobacteriaInternational Journal of Antimicrobial Agents, 2010
- An Official ATS/IDSA Statement: Diagnosis, Treatment, and Prevention of Nontuberculous Mycobacterial DiseasesAmerican Journal of Respiratory and Critical Care Medicine, 2007
- Clarithromycin and ethambutol with or without clofazimine for the treatment of bacteremicAIDS, 1997
- The Ecology of the Atypical MycobacteriaArchives of Environmental Health: An International Journal, 1971